July 10, 2019
Orexo prepays part of the corporate bond loan
Media
July 10, 2019
MIPS APPOINTS NEW CFO
July 09, 2019
Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma
July 01, 2019
Strongbridge Biopharma plc Added to the Russell 3000® and Microcap® Indexes
June 28, 2019
Oncopeptides has completed a directed share issue of approximately SEK 727 million
June 25, 2019
MIPS ACQUIRES THE BRAND GLIDEWEAR AND THE ASSOCIATED PATENT RIGHTS
June 24, 2019
Karo Pharma acquires Trimb for MSEK 3,400
June 19, 2019
GenSight Biologics expands its Board of Directors with the appointments of Maritza McIntyre and Sofinnova Partners
June 16, 2019
New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
June 14, 2019
New Data Presented at 24th EHA Congress from Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)